1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Jackson, P.J. Mcnulty, J.C. Yang, Y.K. Thompson, D.A. Chai, B. Gantz, I. Barsh, G.S. Millhauser, G.M. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Biochemistry BICHAW 0033 0006-2960 41 7565 7572 10.1021/bi012000x 12056887 Design, pharmacology, and NMR structure of a minimized cystine knot with agouti-related protein activity. 2002 US Biochemistry BICHAW 0033 0006-2960 40 15520 15527 10.1021/bi0117192 High Resolution NMR Structure of the Chemically-Synthesized Melanocortin Receptor Binding Domain of Agrp(87-132) of the Agouti-Related Protein. 2001 10.2210/pdb1mr0/pdb pdb_00001mr0 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 THIS IS A RATIONALLY MINIMIZED FRAGMENT OF THE FULLY ACTIVE C-TERMINAL DOMAIN OF THE HUMAN AGOUTI-RELATED PROTEIN AGRP(87-132). THIS FRAGMENT HAS REMOVED FROM IT THE LARGELY DISORDERED C-TERMINAL 12 RESIDUES, YET RETAINS THE SAME BASIC STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF THE LARGER FRAGMENT. 3912.590 AGOUTI RELATED PROTEIN RESIDUES 87-120 C105A 1 syn polymer no no CVRLHESCLGQQVPCCDPAATCYCRFFNAFCYCR CVRLHESCLGQQVPCCDPAATCYCRFFNAFCYCR A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n database_2 pdbx_struct_assembly pdbx_struct_oper_list struct_ref_seq_dif repository Initial release Version format compliance Version format compliance Database references Derived calculations 1 0 2002-10-02 1 1 2008-04-28 1 2 2011-07-13 1 3 2021-10-27 _database_2.pdbx_DOI _database_2.pdbx_database_accession _struct_ref_seq_dif.details 2002-10-02 SPRSDE AGRP(87-132) AGRP(87-120:C105A) Non-superimposed structures, same structure family RCSB Y RCSB 2002-09-17 REL THE PROTEIN WAS CHEMICALLY SYNTHESIZED. THE SEQUENCE OF THE PROTEIN IS NATURALLY FOUND IN HOMO SAPIENS. THE SYNTHETIC METHOD IS STANDARD SOLID-PHASE SYNTHESIS FOLLOWED BY AQUEOUS OXIDATIVE FOLDING. sample THE NOESY, TOCSY AND DQF-COSY EXPERIMENTS WERE PERFORMED AT 800 MHZ; THE HX STUDY WAS CONDUCTED AT 500 MHZ. target function 1000 40 2D-NOESY DQF-COSY TOCSY TOCSY(HX) 20 mM PERDEUTERATED ACETIC ACID 5.0 1 atm 288 K 200 mM PERDEUTERATED ACETIC ACID 4.0 1 atm 288 K STRUCTURE CALCULATIONS WERE ASSISTED WITH AUTOMATED ASSIGNMENT. FINAL STRUCTURES WERE CALCULATED USING 602 NOE-BASED UPPER LIMIT RESTRAINTS AND 23 ALPHA-TO- AMIDE 3-BOND J-COUPLING CONSTANTS. torsion angle dynamics 1 lowest target function 1.7 MM AGRP(87-120 NATURAL ABUNDANCE OF ALL NUCLEI. pH 5.0 20 mM PERDEUTERATED ACETIC ACID 1.6 MM AGRP(87-120; C105A), NATURAL ABUNDANCE OF ALL NUCLEI. pH 4.0 200 mM PERDEUTERATED ACETIC ACID Krish Krishamurthy, Evan Williams, Steve Cheathum, Frtis Vosman, Dan Iverson, Michael Carlisle, Dan Steele, James Welch collection VNMR 6.1B Department of Chemistry,Carlsberg Laboratory, Copenhagen, Denmark processing MNMR 940501 Guntert, P., Mumenthaler, C., and Wuthrich, K. structure solution DYANA 1.5 Bartels, C., Xia, T. H., Billeter, M., Guntert, P., and Wuthrich, K. data analysis XEASY 1.2 Guntert, P., Mumenthaler, C., and Wuthrich, K. refinement DYANA 1.5 800 Varian UNITYPLUS 500 Varian UNITYPLUS CYS 1 n 1 CYS 1 A VAL 2 n 2 VAL 2 A ARG 3 n 3 ARG 3 A LEU 4 n 4 LEU 4 A HIS 5 n 5 HIS 5 A GLU 6 n 6 GLU 6 A SER 7 n 7 SER 7 A CYS 8 n 8 CYS 8 A LEU 9 n 9 LEU 9 A GLY 10 n 10 GLY 10 A GLN 11 n 11 GLN 11 A GLN 12 n 12 GLN 12 A VAL 13 n 13 VAL 13 A PRO 14 n 14 PRO 14 A CYS 15 n 15 CYS 15 A CYS 16 n 16 CYS 16 A ASP 17 n 17 ASP 17 A PRO 18 n 18 PRO 18 A ALA 19 n 19 ALA 19 A ALA 20 n 20 ALA 20 A THR 21 n 21 THR 21 A CYS 22 n 22 CYS 22 A TYR 23 n 23 TYR 23 A CYS 24 n 24 CYS 24 A ARG 25 n 25 ARG 25 A PHE 26 n 26 PHE 26 A PHE 27 n 27 PHE 27 A ASN 28 n 28 ASN 28 A ALA 29 n 29 ALA 29 A PHE 30 n 30 PHE 30 A CYS 31 n 31 CYS 31 A TYR 32 n 32 TYR 32 A CYS 33 n 33 CYS 33 A ARG 34 n 34 ARG 34 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 A N TYR 23 A N TYR 23 A O TYR 32 A O TYR 32 5 A A O H VAL CYS 2 16 1.52 7 A A O H VAL CYS 2 16 1.58 8 A A H OE1 ARG GLU 3 6 1.55 9 A A O H VAL CYS 2 16 1.56 12 A A H OE1 ARG GLU 3 6 1.52 13 A A H OE1 ARG GLU 3 6 1.57 15 A A O H VAL CYS 2 16 1.53 19 A A O H VAL CYS 2 16 1.54 22 A A O H VAL CYS 2 16 1.55 23 A A H O VAL PRO 2 14 1.59 23 A A O H VAL CYS 2 16 1.59 26 A A O H VAL CYS 2 16 1.57 29 A A H OE1 ARG GLU 3 6 1.54 31 A A O H VAL CYS 2 16 1.50 31 A A H O VAL PRO 2 14 1.57 33 A A HG1 O THR ARG 21 34 1.59 36 A A O H VAL CYS 2 16 1.50 38 A A H O VAL PRO 2 14 1.54 40 A A O H VAL CYS 2 16 1.52 1 A HIS 5 -84.40 46.37 1 A SER 7 -39.46 156.54 1 A LEU 9 -38.71 115.59 1 A CYS 22 -65.92 91.22 1 A PHE 26 -90.35 -156.64 1 A ALA 29 -148.56 -85.50 2 A HIS 5 -86.09 45.62 2 A SER 7 -37.61 148.89 2 A CYS 22 -61.15 84.43 2 A PHE 26 -83.58 -154.68 2 A ALA 29 -155.79 -72.62 3 A HIS 5 -86.67 45.43 3 A SER 7 -32.00 141.43 3 A PHE 26 -78.66 -156.39 3 A ALA 29 -155.59 -79.80 4 A HIS 5 -93.35 44.75 4 A SER 7 -37.16 154.56 4 A CYS 22 -60.58 84.35 4 A PHE 26 -80.72 -155.60 4 A ALA 29 -155.42 -80.01 5 A HIS 5 -87.96 45.87 5 A SER 7 -36.97 154.61 5 A LEU 9 -39.91 117.43 5 A CYS 22 -61.23 82.32 5 A PHE 26 -91.31 -157.13 5 A ALA 29 -155.89 -39.17 6 A HIS 5 -97.17 47.15 6 A SER 7 -35.14 150.95 6 A CYS 22 -62.01 83.60 6 A PHE 26 -80.31 -156.66 6 A ALA 29 -155.43 -79.27 7 A HIS 5 -85.16 45.61 7 A SER 7 -36.33 151.56 7 A CYS 22 -63.96 85.31 7 A PHE 26 -80.98 -156.13 7 A ALA 29 -155.60 -78.11 8 A HIS 5 -84.99 47.14 8 A SER 7 -34.09 149.30 8 A CYS 22 -61.85 83.22 8 A PHE 26 -80.38 -156.38 8 A ALA 29 -155.57 -79.44 9 A HIS 5 -95.57 48.68 9 A SER 7 -40.38 157.38 9 A LEU 9 -47.77 106.10 9 A CYS 22 -57.81 84.63 9 A PHE 26 -80.13 -156.23 9 A ALA 29 -155.51 -79.04 10 A HIS 5 -92.25 46.57 10 A SER 7 -42.08 158.39 10 A LEU 9 -45.07 107.29 10 A PRO 18 -75.09 -83.62 10 A ALA 19 -84.32 46.15 10 A CYS 22 -58.38 86.32 10 A PHE 26 -80.75 -156.23 10 A ALA 29 -155.42 -72.45 11 A HIS 5 -84.94 45.81 11 A SER 7 -37.57 153.60 11 A LEU 9 -37.57 116.31 11 A ALA 19 -91.82 30.99 11 A CYS 22 -61.37 80.08 11 A PHE 26 -116.04 -165.91 11 A ALA 29 -155.57 -94.91 12 A HIS 5 -86.27 46.13 12 A SER 7 -34.96 150.91 12 A CYS 22 -60.92 82.87 12 A PHE 26 -96.95 -156.19 12 A ALA 29 -156.03 -39.79 13 A HIS 5 -84.84 45.36 13 A SER 7 -35.36 145.75 13 A CYS 22 -60.95 84.80 13 A PHE 26 -79.55 -154.53 13 A ASN 28 -146.91 29.05 13 A ALA 29 -96.04 -84.87 14 A HIS 5 -89.98 44.48 14 A SER 7 -37.23 154.81 14 A LEU 9 -37.14 111.81 14 A PRO 18 -74.93 -83.81 14 A CYS 22 -59.86 86.47 14 A PHE 26 -81.02 -156.42 14 A ALA 29 -155.39 -70.51 15 A HIS 5 -86.49 45.05 15 A SER 7 -39.41 153.39 15 A LEU 9 -37.51 119.75 15 A CYS 22 -64.26 84.18 15 A PHE 26 -79.71 -156.01 15 A ALA 29 -155.55 -79.78 16 A HIS 5 -85.58 45.22 16 A SER 7 -34.26 143.97 16 A ALA 19 -92.69 32.99 16 A CYS 22 -60.61 80.63 16 A PHE 26 -113.67 -165.00 16 A ALA 29 -155.64 -94.98 17 A HIS 5 -88.94 45.89 17 A SER 7 -34.76 150.91 17 A ALA 19 -92.06 30.49 17 A CYS 22 -63.67 79.47 17 A PHE 26 -87.93 -155.89 17 A ALA 29 -150.12 -84.42 18 A HIS 5 -96.81 45.83 18 A SER 7 -46.69 152.95 18 A CYS 22 -60.42 81.68 18 A PHE 26 -80.86 -155.75 18 A ALA 29 -155.79 -70.46 19 A HIS 5 -85.75 46.63 19 A SER 7 -39.11 155.13 19 A LEU 9 -36.93 127.02 19 A CYS 22 -60.04 83.96 19 A PHE 26 -81.61 -155.90 19 A ALA 29 -155.64 -80.26 20 A HIS 5 -84.85 46.03 20 A SER 7 -37.76 155.93 20 A CYS 22 -66.84 89.72 20 A PHE 26 -89.67 -154.47 20 A ALA 29 -145.04 -78.79 21 A HIS 5 -84.04 47.15 21 A SER 7 -37.66 152.74 21 A ALA 19 -95.40 38.99 21 A CYS 22 -51.60 87.85 21 A PHE 26 -79.39 -157.58 21 A ALA 29 -153.53 -71.87 22 A HIS 5 -86.85 44.92 22 A CYS 22 -59.13 85.43 22 A PHE 26 -93.29 -156.19 22 A ALA 29 -156.17 -40.04 23 A HIS 5 -96.50 47.17 23 A SER 7 -43.73 154.70 23 A LEU 9 -40.00 111.39 23 A CYS 22 -47.12 90.07 23 A PHE 26 -118.16 -166.67 23 A ALA 29 -155.21 -95.35 24 A HIS 5 -86.80 45.87 24 A SER 7 -34.30 147.59 24 A ALA 19 -91.53 30.53 24 A CYS 22 -61.87 82.46 24 A ALA 29 -155.39 -83.69 25 A HIS 5 -84.38 46.20 25 A SER 7 -36.40 153.24 25 A LEU 9 -39.12 110.67 25 A ALA 19 -93.02 33.66 25 A CYS 22 -59.31 83.65 25 A PHE 26 -115.54 -164.10 25 A ALA 29 -155.84 -48.55 26 A HIS 5 -84.74 46.04 26 A SER 7 -39.58 160.29 26 A LEU 9 -38.94 100.39 26 A CYS 22 -63.74 84.55 26 A PHE 26 -83.45 -155.45 26 A ALA 29 -155.56 -71.19 27 A HIS 5 -97.57 46.90 27 A SER 7 -47.94 157.20 27 A LEU 9 -39.58 113.26 27 A PRO 18 -75.01 -84.66 27 A ALA 19 -84.93 45.62 27 A CYS 22 -55.71 88.37 27 A PHE 26 -110.77 -166.08 27 A ALA 29 -155.48 -92.81 28 A HIS 5 -85.55 45.74 28 A SER 7 -31.73 145.10 28 A CYS 22 -66.06 81.52 28 A PHE 26 -97.16 -157.61 28 A ALA 29 -155.48 -78.78 29 A HIS 5 -84.91 45.69 29 A SER 7 -32.58 145.31 29 A ALA 19 -94.61 30.65 29 A CYS 22 -62.07 80.04 29 A PHE 26 -103.70 -158.67 29 A ALA 29 -155.54 -86.91 30 A HIS 5 -87.68 43.05 30 A SER 7 -36.71 146.69 30 A PRO 18 -75.04 -83.97 30 A CYS 22 -62.67 86.08 30 A PHE 26 -95.81 -156.57 30 A ALA 29 -155.79 -40.39 31 A HIS 5 -83.38 49.85 31 A SER 7 -40.46 155.91 31 A LEU 9 -43.12 96.89 31 A CYS 22 -57.65 88.22 31 A PHE 26 -88.50 -155.38 31 A ALA 29 -147.82 -83.70 32 A HIS 5 -84.04 48.00 32 A SER 7 -38.08 153.28 32 A LEU 9 -37.91 105.41 32 A CYS 22 -57.81 86.54 32 A PHE 26 -87.53 -151.09 32 A ASN 28 -148.62 30.12 33 A HIS 5 -89.43 47.52 33 A SER 7 -40.16 152.59 33 A LEU 9 -38.70 118.11 33 A ALA 19 -95.17 31.98 33 A CYS 22 -61.82 81.73 33 A PHE 26 -93.27 -159.72 33 A ALA 29 -155.49 -72.43 34 A HIS 5 -83.72 47.46 34 A SER 7 -39.11 153.39 34 A ALA 19 -93.36 34.20 34 A CYS 22 -62.24 81.02 34 A PHE 26 -80.47 -156.58 34 A ALA 29 -155.61 -77.70 35 A HIS 5 -86.11 45.67 35 A SER 7 -32.73 146.77 35 A CYS 22 -61.42 83.96 35 A PHE 26 -91.37 -156.86 35 A ALA 29 -155.96 -39.05 36 A HIS 5 -84.75 46.24 36 A SER 7 -38.01 151.39 36 A CYS 22 -65.76 75.49 36 A PHE 26 -88.29 -155.90 36 A ALA 29 -150.11 -83.73 37 A HIS 5 -86.60 45.34 37 A LEU 9 -55.85 95.47 37 A ALA 19 -93.54 35.50 37 A CYS 22 -57.72 85.97 37 A PHE 26 -85.98 -155.97 37 A ALA 29 -155.56 -71.24 38 A HIS 5 -95.68 46.73 38 A SER 7 -44.61 155.69 38 A LEU 9 -39.27 112.28 38 A PRO 18 -75.13 -84.81 38 A ALA 19 -84.34 48.82 38 A CYS 22 -59.03 88.38 38 A ALA 29 -155.66 -52.13 39 A HIS 5 -97.38 45.89 39 A SER 7 -38.45 157.07 39 A ALA 19 -92.82 30.00 39 A CYS 22 -58.31 86.94 39 A CYS 24 -127.07 -149.78 39 A ARG 25 -163.62 -64.32 39 A PHE 26 -83.09 -155.14 39 A ALA 29 -156.13 -75.17 40 A HIS 5 -84.28 46.50 40 A ALA 19 -95.71 38.50 40 A CYS 22 -53.95 88.19 40 A CYS 24 -122.34 -152.36 40 A ARG 25 -162.51 -63.37 40 A PHE 26 -83.51 -154.69 40 A ALA 29 -156.07 -76.01 SOLUTION NMR STRUCTURE OF AGRP(87-120; C105A) 1 N N disulf 1.997 A CYS 1 A SG CYS 1 1_555 A CYS 16 A SG CYS 16 1_555 disulf 2.106 A CYS 8 A SG CYS 8 1_555 A CYS 22 A SG CYS 22 1_555 disulf 1.993 A CYS 15 A SG CYS 15 1_555 A CYS 33 A SG CYS 33 1_555 disulf 1.982 A CYS 24 A SG CYS 24 1_555 A CYS 31 A SG CYS 31 1_555 SIGNALING PROTEIN RATIONAL PROTEIN DESIGN, ICK, INHIBITOR CYSTINE KNOT, AGRP, AGOUTI-RELATED PROTEIN, MELANOCORTIN, SIGNALING PROTEIN AGRP_HUMAN UNP 1 87 O00253 CVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCR 87 120 1MR0 1 34 O00253 A 1 1 34 1 CYS engineered mutation ALA 19 1MR0 A O00253 UNP 105 19 2 anti-parallel A THR 21 A THR 21 A CYS 24 A CYS 24 A CYS 31 A CYS 31 A ARG 34 A ARG 34 1 P 1